Clinical Trial Update: Feasibility of Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease [Phase 2]

View source ↗

Summary

Phase 2 feasibility study of empagliflozin in autosomal dominant polycystic kidney disease; the trial is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autosomal Dominant Polycystic Kidney Disease

Drugs mentioned

• Empagliflozin (empagliflozin)

Snippet

Sponsor: University of Colorado, Denver | Conditions: Polycystic Kidney, Autosomal Dominant | Phase 2 | Status: ACTIVE_NOT_RECRUITING